H1 2025 Trading Update
H1 2025 revenues flat at £25.2m but gross margins expanded to 50% and adjusted EBITDA grew 9% in constant currency.
vs expectations: in line
- H1 2025 Revenues £25.2m (prior £25.2m)
- Gross margin 50% (prior 48%)
- Adjusted EBITDA growth (constant currency) 9%
- Cash balances £16.9m (prior £14.3m)
- Hematology revenue growth 8%
- β-HB revenue growth 12%
Select text to share a quote on X · sign in to keep highlights & notes in your EKF notes
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics business, provides an unaudited trading update for the six months ended 30 June 2025 ("H1 2025"), a period showing further improvement in gross margins, earnings growth and cash generation, in-line with management expectations.
H1 2025 revenues were £25.2m (H1 2024: £25.2m), in-line with management expectations following completion of the rationalisation process last year which enabled a greater commercial focus on higher margin products and services. As a result, gross margins further improved to 50% (H1 2024: 48%) and adjusted EBITDA1 showed continued growth. In constant currency terms, revenues and adjusted EBITDA grew year-on-year by 2% and 9% respectively.
Strong cash generation continued with cash balances as at 30 June 2025 of £16.9m (31 December 2024: £14.3m), including cash balances in Russia of £1.9m (31 December 2024: £1.3m). The Company has no bank borrowings and cash balances are after the deployment of £1m of on-market purchases in the initial share buyback programme, and the continued investment for growth that is part of the five-year strategic development plan for the business.
The implementation of the five-year plan continues in-line with management expectations, with a strong revenue performance from the key growth areas of Hematology (8% increase year-on-year) and β-HB (12% increase year-on-year). Diabetes sales have stabilised providing a steady performance in the first half. The pipeline for contract manufacturing and fermentation opportunities is encouraging with a number of high value prospects now in the advanced stage of discussions. The Company hopes to update shareholders on the conversion of these opportunities in due course.
The Company remains on track to deliver growth at the revenue and adjusted EBITDA levels for FY 2025 in-line with market expectations2.
EKF will announce unaudited results for H1 2025 on 16 September 2025.
1Earnings before interest, tax, depreciation and amortisation, excluding exceptional items.
²Management understands consensus revenue and Adjusted EBITDA forecasts for FY 2025 to be £53.6m and £12.4m respectively.
The person responsible for arranging the release of this Announcement
on behalf of the Company is Gavin Jones, Chief Executive Officer.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com |
| Julian Baines, Executive Chair | via Walbrook PR |
| Gavin Jones, Chief Executive Officer | |
| Stephen Young, Chief Financial Officer | |
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 |
| Phil Davies / Oliver Platts | |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.